";s:4:"text";s:3935:" Get the latest money, tax, work and property news, straight to your inbox. USD 10 per month if there’s been no login for 12 months The Australian sharemarket shot higher on Monday with reports a therapeutic developed by Gilead Sciences was proving effective against COVID-19 boosting investor sentiment.Investors were buoyed by news that Gilead Sciences' antiviral drug remdesivir had shown significantly improved clinical recovery and reduced the risk of death in COVID-19 patients , according to a late-stage study.The announcement was timely given the significant increase in new cases both in the US and Australia.
Optional, only if you want us to follow up with you.Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.finder.com.au is one of Australia's leading comparison websites. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. We encourage you to use the tools and information we provide to compare your options.Where our site links to particular products or displays 'Go to site' buttons, we may receive a commission, referral fee or payment when you click on those buttons or apply for a product. The S&P/ASX …
Commonwealth Bank rose 2.1 per cent to $72.12, Westpac firmed 1.8 per cent to $17.97, NAB advanced 1.7per cent to $18.17 and ANZ lifted 1.9 per cent to $18.64. The largest ‘COVID-19-aligned’ health companies are arguably CSL (ASX:CSL), respiratory device company ResMed (ASX:RMD), infection control business Nanosonics (ASX:NAN), and stem cell biotech Mesoblast (ASX:MSB). Here are five big days that will tell the story of the broader market. The approval is for adults and adolescent patients with severe COVID-19 symptoms and have been hospitalised, the Australian regulator said. Please refer to our The Finder app is here. But to understand United Overseas Australia better, we need to consider many other factors. Gilead Sciences Inc. and Galapagos NV said their arthritis drug got a scientific recommendation from the European Medicines Agency to grant marketing authorization in Europe. product providerWe cannot provide you with personal advice or recommendations We provide tools so you can sort and filter these lists to highlight features that matter to you.We try to take an open and transparent approach and provide a broad-based comparison service. S&P/ASX Australian Technology ETF. AUD 50 per quarter if you make fewer than three trades in that period As it happens, United Overseas Australia's TSR for the last 5 years was 62%, which exceeds the share price return mentioned earlier. ALL ORDS 6,160.10-9.50 (-0.15%) ASX 200 6,033.90-10.30 (-0.17%) AUD/USD 0.7137-0.0012 (-0.17%) Free Sign up. The Australian sharemarket shot higher on Monday with reports a therapeutic developed by Gilead Sciences was proving effective against COVID-19 boosting investor sentiment. The Nasdaq posted its sixth record closing high in seven days on Friday, as an analysis of Gilead Sciences Inc's antiviral drug to treat COVID-19 yielded positive results. "The major banks led the gains. Shares in US drugmaker Gilead Sciences were whipsawed for the second time in a week after a summary of a Chinese trial of its COVID-19 drug appeared to show that it was a failure.